2023
Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original Research
2021
OFF-LABEL USE OF DRUG COATED BALLOONS AND STENTS IN PATIENTS WITH FEMOROPOPLITEAL AND ADVANCED CHRONIC KIDNEY DISEASE. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE
Dominguez Y, Pichert M, Alabi O, Huang J, Qurat-Ul-Ain J, Arham A, Brice A, Ahmed Z, Chaar C, Stacy M, Turner J, Smolderen K, Hurtado C. OFF-LABEL USE OF DRUG COATED BALLOONS AND STENTS IN PATIENTS WITH FEMOROPOPLITEAL AND ADVANCED CHRONIC KIDNEY DISEASE. INSIGHTS FROM THE VASCULAR QUALITY INITIATIVE. Journal Of The American College Of Cardiology 2021, 77: 1012. DOI: 10.1016/s0735-1097(21)02371-8.Peer-Reviewed Original Research
2020
Renal Disease in Older Adults
Turner J, Sharma D. Renal Disease in Older Adults. 2020, 265-276. DOI: 10.1007/978-3-319-47771-8_17.Chapters
2018
Barriers to Advance Care Planning in End-Stage Renal Disease: Who is to Blame, and What Can be Done?
Kelley AT, Turner J, Doolittle B. Barriers to Advance Care Planning in End-Stage Renal Disease: Who is to Blame, and What Can be Done? The New Bioethics 2018, 24: 150-157. PMID: 29513084, DOI: 10.1080/20502877.2018.1438772.Peer-Reviewed Case Reports and Technical NotesConceptsAdvance care planningCare planningEnd-stage renal diseaseChronic kidney diseaseCourse of diseaseRenal diseaseKidney diseaseIntensive treatmentAdvance carePatient valuesCognitive declinePatientsSignificant mortalityClinical literatureDecision-making capacityDaily practiceDiseaseYears of supportPhysiciansConvincing evidenceMore trainingMorbidityHospitalClinicMortality